Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year

Immuneering said Wednesday its MEK inhibitor pill helped keep 86% of pancreatic cancer patients alive at nine months when given in the first-line setting along with chemotherapy in a mid-stage trial. The drug, called atebimetinib ...